Friday, December 17, 2021 7:10:32 PM
The biological Inovio arrives in Veracruz as a high-tech and effective alternative against Covid-19, therefore, Comprehensive Counseling Training for the Clinical Research Center (FAICIC) will have 250 antigens to apply to the same number of 18-year-olds in Go ahead that they have never been vaccinated against the coronavirus, nor are they pregnant or are currently breastfeeding; as well as those who suffer from chronic diseases such as: diabetes, hypertension, cancer, HIV, obesity, with allergies, among others.
The general director of the Faicic Clinical Research Center, Sharzy Molina Guízar, explained that it is a very safe antigen, which has the characteristic that it is not injected, but through a shot in the arm that will impact at the cellular level, by means of a electrode, as it has a very different molecular composition that makes it different from those already known, because it travels at the cellular level, causing immunity in 24 hours, longer and more efficiently.
“Previous vaccines were given through an injection in the arm; This also goes in the arm, but it is done by means of a device that is like a pistol, which what it does is that here in the arm, in the muscle, a shot is fired that does not cut, that does not open the skin, It does not hurt, it is painless and this allows it to travel at the cellular level and how do we achieve immunity in 24 hours? We achieve this because it travels so fast in the cells that what it does is a reproduction, they cause an excitation to the cells that make one infect the other very quickly and, then, we can go from one to 10, from 10 to 100 , from 100 to a thousand and we not only cause an immunity for a longer time, but also, much more effective ”.
He explained that Inovio decided to do it this way, since the existing vaccines that are applied in the injected arm, its route at the muscular level generated an immunity of 28 to more than 40 days, depending on the organism, due to its composition and its journey in the body, which also caused other allergic reactions or altered some parts of the body, while Inovio causes immediate immunity.
Likewise, Molina Guízar recognized that, based on studies carried out, Inovio has a high proven efficacy against the Ómicron variant, although investigations continue, which is why it adds to the list of qualities of this antigen.
“This vaccine, so far, is showing an efficacy of 95.5% in the first application that is given at 24 hours. This vaccine has two doses (two applications): on day zero, which is the day the vaccine is applied, and at 28 days, ”said the interviewee.
The general director of Faicic admitted that there are side effects similar to those of injected vaccines, such as: headache, nausea, dizziness, weakness, fever, among others, which are treatable and will be treated by the medical staff of the center of research.
In this sense, he recognized that there is still a large number of the population not vaccinated against this disease for various reasons, such as: fear, resistance, lack of information, among others.
“After two years, we already have a lot of experience, we have seen how to improve it and we invited the population that was afraid to come because now we have a very safe vaccine; It is also aimed at those people who, for example, who are allergic, who have chronic degenerative diseases ”.
Sharzy Molina highlighted that they will be working every day for the application of Inovio, including holidays such as December 25 and January 1, 2022, for which, he invited citizens with these characteristics to register in this application, since It will serve the Veracruz and foreign population, where in the case of the latter, they will be supported with the transfer, therefore, they require social leaders who support with this process the population of marginalized areas whose expenses are assumed by Faicic.
Inovio vaccine arrives in Veracruz, with immunity in 24 hours from the 1st dose
He added that in addition to the support for the transfer to the Faicic headquarters, the patients will be provided with: medical, nutritional, psychological consultation, laboratory studies and for a year and a half they will remain in contact with them, with open consultation for any subsequent symptom or condition that they may present.
He recalled that Faicic is a research center that seeks to improve people's health and lives, through studies and in coordination with recognized pharmaceutical companies.
Interested parties may access the website: https://faicic.com.mx/formulario_covid.php, on their social networks on Facebook such as https://www.facebook.com/Faicic and instagram; Likewise , they can call the phone: 2299327808 .
https://www-eldictamen-mx.translate.goog/noticias-de-veracruz/boca-ver/llega-a-veracruz-vacuna-inovio-con-inmunidad-en-24-horas-desde-la-1a-dosis/?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM